ElsaLys Biotech SA

ElsaLys Biotech is clinical stage immunooncology company designing and developing new generation of #therapeuticantibodies targeting #tumormicroenvironment #cancer #ophtalmology ElsaLys Biotech is a spin-off from Transgene R&D, and is developing novel monoclonal antibodies against first-in-class targets for the treatment of cancer & inflammatory diseases.

The portfolio of ElsaLys Biotech is composed of 4 novel undisclosed projects issued from well-known academic groups and partners such as EFS, Curie Institute, Tumor Institute of Turin and SATT-Sud Est.

Management

Technology

Deals/Partnering

Research Pipeline

Funding

BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.elsalysbiotech.co

Founded2013

Disease Focus
Immunology
Opthalmic
Oncology

Development StageClinical

STOCK CODENon Listed

Address
Pepiniere de Hautepierre 8 avenue Dante, CS 70033 F-67087
Strasbourg
France

Email
contact@elsalysbiotech.com

Contact Number
+33 4 37 28 73 00

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Dec 2016, ELSALYS BIOTECH acquired development and marketing rights for TG3003 anti-CD115 (now ELB041) from TRANSGENE SA; a monoclonal antibody that inhibits a highly immunosuppressive macrophage subpopulation: type-2 macrophages. TRANSGENE, is one of ELSALYS BIOTECHs founding shareholders and further financal details remains undisclosed.

In May 2013, ElsaLys Biotech recieved its first round of financing of 2.1M from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.